QuickLinks -- Click here to rapidly navigate through this document

Exhibit 12

E. I. DU PONT DE NEMOURS AND COMPANY

COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
(Dollars in millions)

		Years Ended December 31
		2004			2003			2002			2001			2000
Income from Continuing Operations Before Extraordinary Item and Cumulative Effect of a Change In Accounting Principles		$	1,780		$	1,002		$	1,841		$	4,328	(a)	$	2,314
(Benefit from) Provision for Income Taxes			(329	)		(930	)		185			2,467			1,072
Minority Interests in (Losses) Earnings of Consolidated Subsidiaries			(9	)		71			98			49			61
Adjustment for Companies Accounted for by the Equity Method			99			360			45			93			(109	)
Capitalized Interest			(17	)		(29	)		(45	)		(62	)		(69	)
Amortization of Capitalized Interest			365	(b)		119	(b)		59			61			65
			1,889			593			2,183			6,936			3,334
Fixed Charges:
	Interest and Debt Expense		362			347			359			590			810
	Capitalized Interest		17			29			45			62			69
	Rental Expense Representative of Interest Factor		91			90			82			78			70
			470			466			486			730			949
Total Adjusted Earnings Available for Payment of Fixed Charges		$	2,359		$	1,059		$	2,669		$	7,666		$	4,283
Number of Times Fixed Charges are Earned			5.0			2.3			5.5			10.5			4.5

(a)

Includes $3,866 after-tax gain on the sale of DuPont Pharmaceuticals to Bristol-Myers Squibb.

(b)

Includes write-off of capitalized interest associated with exiting certain businesses.

QuickLinks

Exhibit 12